Magnetic resonance delta radiomics to track radiation response in lung tumors receiving stereotactic MRI-guided radiotherapy

Introduction: Lung cancer is a leading cause of cancer-related mortality, and stereotactic body radiotherapy (SBRT) has become a standard treatment for early-stage lung cancer. However, the heterogeneous response to radiation at the tumor level poses challenges. Currently, standardized dosage regimens lack adaptation based on individual patient or tumor characteristics. Thus, we explore the potential of delta radiomics from on-treatment magnetic resonance (MR) imaging to track radiation dose response, inform personalized radiotherapy dosing, and predict outcomes. Methods: A retrospective study of 47 MR-guided lung SBRT treatments for 39 patients was conducted. Radiomic features were extracted using Pyradiomics, and stability was evaluated temporally and spatially. Delta radiomics were correlated with radiation dose delivery and assessed for associations with tumor control and survival with Cox regressions. Results: Among 107 features, 49 demonstrated temporal stability, and 57 showed spatial stability. Fifteen stable and non-collinear features were analyzed. Median Skewness and surface to volume ratio decreased with radiation dose fraction delivery, while coarseness and 90th percentile values increased. Skewness had the largest relative median absolute changes (22%-45%) per fraction from baseline and was associated with locoregional failure (p=0.012) by analysis of covariance. Skewness, Elongation, and Flatness were significantly associated with local recurrence-free survival, while tumor diameter and volume were not. Conclusions: Our study establishes the feasibility and stability of delta radiomics analysis for MR-guided lung SBRT. Findings suggest that MR delta radiomics can capture short-term radiographic manifestations of intra-tumoral radiation effect.

Fully Automated Deep Learning-enabled Detection for Hepatic Steatosis on Computed Tomography: A Multicenter International Validation Study

Despite high global prevalence of hepatic steatosis, no automated diagnostics demonstrated generalizability in detecting steatosis on multiple international datasets. Traditionally, hepatic steatosis detection relies on clinicians selecting the region of interest (ROI) on computed tomography (CT) to measure liver attenuation. ROI selection demands time and expertise, and therefore is not routinely performed in populations. To automate the process, we validated an existing artificial intelligence (AI) system for 3D liver segmentation and used it to purpose a novel method: AI-ROI, which could automatically select the ROI for attenuation measurements. AI segmentation and AI-ROI method were evaluated on 1,014 non-contrast enhanced chest CT images from eight international datasets: LIDC-IDRI, NSCLC-Lung1, RIDER, VESSEL12, RICORD-1A, RICORD-1B, COVID-19-Italy, and COVID-19-China. AI segmentation achieved a mean dice coefficient of 0.957. Attenuations measured by AI-ROI showed no significant differences (p = 0.545) and a reduction of 71% time compared to expert measurements. The area under the curve (AUC) of the steatosis classification of AI-ROI is 0.921 (95% CI: 0.883 - 0.959). If performed as a routine screening method, our AI protocol could potentially allow early non-invasive, non-pharmacological preventative interventions for hepatic steatosis. 1,014 expert-annotated liver segmentations of patients with hepatic steatosis annotations can be downloaded here: https://drive.google.com/drive/folders/1-g_zJeAaZXYXGqL1OeF6pUjr6KB0igJX.

Deep learning-based detection of intravenous contrast in computed tomography scans

Purpose: Identifying intravenous (IV) contrast use within CT scans is a key component of data curation for model development and testing. Currently, IV contrast is poorly documented in imaging metadata and necessitates manual correction and annotation by clinician experts, presenting a major barrier to imaging analyses and algorithm deployment. We sought to develop and validate a convolutional neural network (CNN)-based deep learning (DL) platform to identify IV contrast within CT scans. Methods: For model development and evaluation, we used independent datasets of CT scans of head, neck (HN) and lung cancer patients, totaling 133,480 axial 2D scan slices from 1,979 CT scans manually annotated for contrast presence by clinical experts. Five different DL models were adopted and trained in HN training datasets for slice-level contrast detection. Model performances were evaluated on a hold-out set and on an independent validation set from another institution. DL models was then fine-tuned on chest CT data and externally validated on a separate chest CT dataset. Results: Initial DICOM metadata tags for IV contrast were missing or erroneous in 1,496 scans (75.6%). The EfficientNetB4-based model showed the best overall detection performance. For HN scans, AUC was 0.996 in the internal validation set (n = 216) and 1.0 in the external validation set (n = 595). The fine-tuned model on chest CTs yielded an AUC: 1.0 for the internal validation set (n = 53), and AUC: 0.980 for the external validation set (n = 402). Conclusion: The DL model could accurately detect IV contrast in both HN and chest CT scans with near-perfect performance.